Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LN Clear all
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
IMPT-514
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 69 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN)
Interventions
CART19
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 22, 2026, 12:01 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
ATA3219
Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions
Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus, SLE, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (Disorder)
Interventions
ONT01 is a small molecule CD11b modulator.
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 22, 2026, 12:01 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Interventions
ADX-097
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced May 22, 2026, 12:01 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
C-CAR168
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
rapcabtagene autoleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
15
States / cities
Birmingham, Alabama • San Bernardino, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Vonsetamig, Odronextamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 12:01 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Refractory Lupus Nephritis, Refractory Systemic Sclerosis
Interventions
TAK-007, Chemotherapy Agents
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Lupus Nephritis, Primary Membranous Nephropathy
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Little Rock, Arkansas • Tustin, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 12:01 AM EDT
Not yet recruiting Phase 4 Interventional
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 12:01 AM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Atacicept, Placebo
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
Huntsville, Alabama • La Jolla, California • La Palma, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced May 22, 2026, 12:01 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Felzartamab
Drug
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Lupus Nephritis
Interventions
ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
37
States / cities
Birmingham, Alabama • La Palma, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Lupus Nephritis
Interventions
None (Observational study)
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • Charlotte, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Ixazomib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
La Jolla, California • Upland, California • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions
Ravulizumab, Placebo, Background Therapy
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
San Dimas, California • Santa Monica, California • South Gate, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
38
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 12:01 AM EDT